Aeolus Pharmaceuticals Announces AEOL 10150 Reduces Lung Damage After Neupogen(R) Treatment Following Radiation Exposure
01 juin 2012 08h58 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jun 1, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2012 Financial Results
14 mai 2012 19h48 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - May 14, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS)
$2.2 million in revenue for second quarter 2012; $4.4...
BARDA Exercises $9.1 Million in Contract Options With Aeolus
16 avr. 2012 08h41 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 16, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
BARDA Delivers Notice of Intent to Exercise Additional Contract Options With Aeolus Worth $9.1 Million
09 avr. 2012 04h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 9, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
BARDA notice of intent to exercise options valued at...
Aeolus Pharmaceuticals Announces Date and Time for Barda Contract and Corporate Update Conference Call
05 avr. 2012 15h39 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 5, 2012) - Aeolus Pharmaceuticals (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus to Present at Roth Capital Partners' 24th Annual Growth Stock Conference
13 mars 2012 06h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Mar 13, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus Announces No-Cost Extension and Modification of Barda Contract Fully Valued at $118 Million to Develop Treatment for Lung Acute Radiation Syndrome
15 févr. 2012 10h35 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 15, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
Restructure driven by additional items added to base...
Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results
13 févr. 2012 17h40 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 13, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
$2.2 million in revenue
Meeting to request...
Aeolus' AEOL 10150 Protects Lung Tissue From Radiation by Modulating PTEN Levels, Reducing Oxidative Stress and Apoptosis
08 févr. 2012 14h35 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 8, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
Data published in the International Journal of Radiation...
Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model Published in the Journal of Neurobiology of Disease
07 févr. 2012 06h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 7, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...